EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost of Serious Infections in Chronic Lymphocytic Leukemia

Sara Carrillo de Albornoz iD, Rainier Arnolda iD, Alisa M Higgins, Erica M Wood, Zoe K McQuilten, Dennis Petrie

Cancer Medicine · 2026

DOI: 10.1002/cam4.71397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Sara Carrillo de Albornoz und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Infections, Cost of Illness, Hospital Costs. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Future Fund, National Health and Medical Research Council Blood Synergy, National Health and Medical Research Council Emerging Leader Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The economic burden of chronic lymphocytic leukemia (CLL) is high, and is projected to increase with the introduction of new targeted treatments and improved survival. These high costs are not only associated with anticancer treatment, but also with the treatment and prevention of CLL symptoms and adverse events. Infections are among the most common adverse events in CLL patients, resulting from immune dysregulation caused by both the underlying disease and treatments. Immunoglobulin replacement therapy (IgRT) is one prophylactic measure used to prevent infections, but its effectiveness in CLL is unclear and costs are substantial. The aim of this paper was to estimate the excess cost associated with serious infections in patients with CLL, and explore other factors that may increase hospitalization costs in Australia.

Methods

We conducted a retrospective longitudinal study of linked hospital data, including 3705 patients with CLL and hospital admissions between July 2016 and June 2022. We estimated the excess cost associated with serious infections, inhospital anticancer treatment and IgRT using generalized linear models with gamma distribution and identity link.

Results

Over the study period, the mean inhospital cost per patient per month was AU$1291 (US$892) and was highest in the month of CLL diagnosis, at AU$4168 (US$2880). The excess cost in the month of a serious infection was AU$22,905 (US$15,829) per patient, and costs remained higher in the subsequent 6 months. The monthly costs associated with IgRT and anticancer treatment were AU$3288 (US$2772) and AU$5223 (US$3609) per patient, respectively.

Conclusion

Our results highlight the high economic burden of serious infections in a large cohort of patients with CLL over a 6‐year period. Further costing studies including costs to the patient and healthcare utilization in the outpatient setting are needed to ascertain the total cost of infections and the overall cost of cancer care in patients with CLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellInfectionsCost of IllnessHospital CostsHumansRetrospective StudiesFemaleMaleAgedAustraliaLongitudinal StudiesHospitalizationMiddle AgedAged, 80 and overHealth Care Costs

Stichwörter der Autor:innen

chronic lymphocytic leukemiacostimmunoglobulininfections

Autor:innen und Institutionen

  • School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
  • Centre for Health Economics, Monash University, Melbourne, Australia.
  • Department of Clinical Haematology, Monash Health, Melbourne, Australia.
  • Department of Haematology, Alfred Health, Melbourne, Australia.

ORCID-Profile: Sara Carrillo de Albornoz, Rainier Arnolda

Förderung

  • Medical Research Future Fund
  • National Health and Medical Research Council Blood Synergy
  • National Health and Medical Research Council Emerging Leader Fellowship
  • National Health and Medical Research Council Investigator grant
  • National Health and Medical Research Council Emerging Leader Investigator

Zitieren

APA

Carrillo de Albornoz, S., Arnolda, R., Higgins, A. M., Wood, E. M., McQuilten, Z. K., & Petrie, D. (2026). Cost of Serious Infections in Chronic Lymphocytic Leukemia. Cancer Medicine. https://doi.org/10.1002/cam4.71397

Vancouver

Carrillo de Albornoz S, Arnolda R, Higgins AM, Wood EM, McQuilten ZK, Petrie D. Cost of Serious Infections in Chronic Lymphocytic Leukemia. Cancer Medicine. 2026. doi:10.1002/cam4.71397

BibTeX
@article{CarrillodeAlbornoz2026,
  author = {Carrillo de Albornoz, Sara and Arnolda, Rainier and Higgins, Alisa M and Wood, Erica M and McQuilten, Zoe K and Petrie, Dennis},
  title = {Cost of Serious Infections in Chronic Lymphocytic Leukemia},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71397}
}
Kostenlos starten →